- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
PSS World Medical buys Medical Imaging
PSS World Medical continues its aggressive acquisition drive. The medical supplies distributor this month announced that it will purchase Medical Imaging Services of Little Rock, AR, a private medical imaging distributor with annual revenues of
PSS World Medical continues its aggressive acquisition drive. The medical supplies distributor this month announced that it will purchase Medical Imaging Services of Little Rock, AR, a private medical imaging distributor with annual revenues of approximately $18 million. The agreement solidifies PSS World's operations in the southwest and south central U.S. and adds to two other recent acquisitions in the region (SCAN 2/18/98).
In other news, the Jacksonville, FL, company this month signed an agreement with SonoSight for exclusive U.S. rights to distribute SonoSight's handheld ultrasound products to private physicians' offices. The deal gives SonoSight access to this market, while PSS World improves the range of medical techology it can offer. In May, SonoSight received 510(k) approval from the Food and Drug Administration for its first handheld ultrasound device, which it plans to release in the second half of 1999.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
